MediSieve
Kerstin Stegmann is an immunologist currently employed at MediSieve Limited since April 2019. Previously, Stegmann served as a Senior Postdoctoral Research Associate at University College London from April 2014 to March 2019, where the main project focused on the role of NK cells in hepatitis B virus infection. Notable achievements include identifying CXCR6 as a marker for liver-resident NK cells and studying their interactions with hepatocytes. Before that, Stegmann was a Postdoctoral Research Fellow at the London School of Hygiene & Tropical Medicine from January 2011 to March 2014, exploring NK cells in malaria models. Additionally, Stegmann held visiting scientist positions at QIMR Berghofer Medical Research Institute and the Medical Research Council Unit in The Gambia. Educational qualifications include a PhD in Immunology of Infectious Diseases from Medizinische Hochschule Hannover, and a Master and Bachelor of Science in Molecular Biotechnology from Technical University of Munich, along with a visiting PhD student experience at Karolinska Institutet.
This person is not in the org chart
This person is not in any teams
MediSieve
1 followers
MediSieve is a multi-award-winning medical device company developing Magnetic Blood Filtration (MBF), a platform technology for the treatment of blood-borne diseases by physically removing disease relevant targets directly from a patient’s bloodstream. MBF is an extracorporeal technology, similar to dialysis. A patient's blood is continuouslycirculated through an external blood loop containing the MediSieve system. Targeted magnetic particles (TB-MPs) are infused into the loop, binding specifically to disease-relevant targets in the patient's blood. The blood then flows through a magnetic filter which captures the particles and bound targets and the remainder of the blood returns to the patient unaffected; the TB-MPs never enter the patient’s body.MediSieve is based at the Imperial Incubator in White City, London. It has dedicated workshop and laboratory facilities (including capacity for ELISAs, Flow Cytometry and human blood testing) in which products are developed and validated.